Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09AX Other drugs for disorders of the musculo-skeletal system
M09AX10 Risdiplam
D11406 Risdiplam (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Risdiplam
D11406 Risdiplam (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D11406 Risdiplam (JAN/USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
D11406 Risdiplam
DG02954 CYP2J2 substrate
D11406 Risdiplam
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D11406 Risdiplam
DG03121 CYP3A7 substrate
D11406 Risdiplam
Unclassified
DG03306 FMO substrate
DG03191 FMO1 substrate
D11406 Risdiplam
DG02950 FMO3 substrate
D11406 Risdiplam
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Signaling molecules
Spliceosome
SMN2
D11406 Risdiplam (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11406
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11406
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11406
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11406
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11406